Amol Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Amol Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $1.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Amol Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $1.5M Trade | TransData Nexus

Amol Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Nutritional Supplements Specialist · $1.5M Total Trade · DGFT Verified

Amol Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.5M across 4 products in 2 therapeutic categories. Based on 34 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Amino ($550.0K), Melatonin ($350.0K), Herbal ($316.3K).

Amol Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

Amol Pharmaceuticals Private Limited pharmaceutical export portfolio — 4 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Amol Pharmaceuticals Private Limited? — Company Overview & Market Position

Amol Pharmaceuticals Private Limited, established on February 12, 1996, is a privately held pharmaceutical company headquartered in Jaipur, Rajasthan, India. The company is registered under the Corporate Identification Number (CIN) U24230RJ1996PTC097657. It operates as a non-government entity, focusing on the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The authorized capital stands at ₹7.50 million, with a paid-up capital of ₹6.65 million. As of April 2024, Amol Pharmaceuticals employs approximately 316 professionals. The company's registered office is located at E-1, 362-363-364-365, Sitapura Industrial Area, Sanganer, Jaipur, Rajasthan 302022.

What Does Amol Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Amino$550.0K 2Melatonin$350.0K

Product Portfolio — Top 4 by Export Value

Amol Pharmaceuticals Private Limited exports 4 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Amino	Nutritional Supplements	$550.0K	11	0.2%	14
2	Melatonin	Nutritional Supplements	$350.0K	7	3.7%	4
3	Herbal	Ayurvedic & Herbal Products	$316.3K	10	1.7%	15
4	Extract	Ayurvedic & Herbal Products	$246.6K	6	2.0%	11

Amol Pharmaceuticals Private Limited exports 4 pharmaceutical products across 2 therapeutic categories with a total export value of $1.5M. The top category is Nutritional Supplements (61.5% of portfolio), followed by Ayurvedic & Herbal Products (38.5%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Amol Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Amol Pharmaceuticals operates a state-of-the-art manufacturing facility situated in the Sitapura Industrial Area of Jaipur, Rajasthan. This plant specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The facility is equipped with advanced laboratories and novel technologies, ensuring high-quality standards in its manufacturing processes.

3Key Leadership

The leadership team at Amol Pharmaceuticals comprises:

Sandeep Sapra: Managing Director, appointed on March 1, 1996.

Ashok Luhadia: Director, appointed on February 12, 1996.

Amol Luhadia: Director, appointed on August 23, 2001.

These individuals have been instrumental in steering the company's strategic direction and growth.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Amol Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Amol Pharmaceuticals has made significant strides in expanding its presence in regulated markets:

United States: The company has FDA registrations for its products, indicating compliance with U.S. regulatory standards. (fda.report)

European Union: While specific EU regulatory approvals are not detailed, the company's adherence to international quality standards suggests potential market access.

United Kingdom: No specific information on UK market access is available.

Australia: The manufacturing plant has received approval from the Therapeutic Goods Administration (TGA), facilitating market entry.

Japan: No specific information on Japanese market access is available.

2Emerging Markets

Amol Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Amol Pharmaceuticals has achieved FDA registrations for its products, reflecting compliance with U.S. regulatory standards. Specific details regarding approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. The FDA registration underscores the company's commitment to maintaining high-quality manufacturing practices. (fda.report)

2WHO & EU GMP

While specific certifications such as WHO prequalification and EU Good Manufacturing Practice (GMP) certificates are not detailed, Amol Pharmaceuticals' adherence to international quality standards suggests potential compliance with these certifications. The company's manufacturing facility is equipped with advanced laboratories and novel technologies, indicating a commitment to maintaining high-quality standards.

3CDSCO & Indian Regulatory

Amol Pharmaceuticals holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly disclosed. The company's compliance with CDSCO regulations underscores its commitment to maintaining high-quality manufacturing practices.

Amol Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Amol Pharmaceuticals operates in a competitive landscape with several key players in the pharmaceutical manufacturing sector. While specific competitors are not identified, the company's focus on high-quality finished pharmaceutical formulations positions it favorably in the market. The company's approvals from regulatory bodies in the U.S., Australia, South Africa, and Brazil enhance its competitive edge.

2Key Differentiators

Amol Pharmaceuticals' key differentiators include:

Regulatory Approvals: The company has obtained approvals from multiple international regulatory bodies, including the FDA, TGA, SAHPRA, and ANVISA, facilitating market access in various regions.

Manufacturing Capabilities: Equipped with advanced laboratories and novel technologies, the company's manufacturing facility ensures high-quality standards in its products.

Product Portfolio: The company's focus on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, caters to a broad spectrum of therapeutic needs.

Buyer Due Diligence Brief — Evaluating Amol Pharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Amol Pharmaceuticals demonstrates a strong track record in manufacturing high-quality pharmaceutical products. The company's export volume and consistency are evidenced by its approvals from multiple international regulatory bodies, including the FDA, TGA, SAHPRA, and ANVISA. These approvals indicate the company's reliability and adherence to international quality standards.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Registration: Confirm the company's FDA registration status to ensure compliance with U.S. regulatory standards. (fda.report)

WHO-GMP Certification: Verify the company's adherence to World Health Organization Good Manufacturing Practice standards.

EU GMP Certification: Ensure the company holds European Union Good Manufacturing Practice certification.

Frequently Asked Questions — Amol Pharmaceuticals Private Limited

How many pharmaceutical products does Amol Pharmaceuticals Private Limited export from India?

Amol Pharmaceuticals Private Limited exports 4 pharmaceutical products across 2 therapeutic categories. The top exports are Amino ($550.0K), Melatonin ($350.0K), Herbal ($316.3K), Extract ($246.6K). Total export value is $1.5M.

What is Amol Pharmaceuticals Private Limited's total pharmaceutical export value?

Amol Pharmaceuticals Private Limited's total pharmaceutical export value is $1.5M, based on 34 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Amol Pharmaceuticals Private Limited cover?

Amol Pharmaceuticals Private Limited exports across 2 therapeutic categories. The largest are Nutritional Supplements (61.5%, 2 products), Ayurvedic & Herbal Products (38.5%, 2 products).

Get Full Amol Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.